Ironwood Pharma (IRWD) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Goldman Sachs raises humanoid robot forecast, sees auto role
- Wall St dips as rising oil prices, hawkish Fed bets pressure stocks
Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update
May 1, 2018 7:55 AM EDTFirst quarter revenue increased 33% year-over-year to $69 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $159 million and commercial margin of 63%
IW-3718 Phase III program expected to initiate in the third quarter of 2018
Phase II sGC programs, praliciguat and olinciguat (IW-1701) continue to progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:... More
